Healthlead Public Company Limited Stocks

THB 6.4Last Updated 27.04.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

THB 50.52M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
THB 6.4
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Good growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Healthlead Public Company Limited, together with its subsidiaries, engages in development, import, and distribution of drugs, pharmaceuticals, cosmetic products, dietary supplements, medical equipment, other health products. It offers medicines, medical supplies, and medical devices, as well as disinfectant and deodorizing products comprising mask products under the iCare, Pharmax, vitaminclub, and Super Drug brands; and dietary supplements under the PRIME and Besuto brand names. The company also engages in the building rental, event organization, and restaurant businesses, as well as operates a medical clinic. It operates a network of 28 pharmacy branches comprising 11 iCare branches, 13 Pharmax branches, 3 vitaminclub branches, and 1 Super Drug branch. Healthlead Public Company Limited was incorporated in 2018 and is headquartered in Nonthaburi, Thailand.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is reasonably priced on P/E, of fair value on E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks